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ABSTRACT
Although allogeneic hematopoietic stem cell transplantation is a potentially curative approach for advanced he-
matologic diseases, its application to elderly people is limited because of their comorbid physical conditions and
lower chance of finding suitable related donors. Umbilical cord blood transplantation with reduced-intensity
pretransplant conditioning (RI-UCBT) is 1 way to avoid these obstacles. We analyzed elderly patients aged
55 years and older with hematologic diseases who underwent RI-UCBT at our institute to assess feasibility
and effectiveness of this treatment approach. Among the 70 patients included, 50 died, 74% of them from non-
relapse causes. Infection was the primary cause of death. Estimated overall survival and progression-free survival
at 2 years were both 23%. In multivariate analyses, standard-risk diseases, age younger than 61 years, grade 0-II
acute graft-versus-host disease, and the absence of preengraftment immune reaction were significantly associ-
ated with better overall survival. RI-UCBT is a potentially curative and applicable approach for elderly patients.
Higher mortality, especially from nonrelapse causes, is the biggest problem to be solved to increase the feasibil-
ity of this approach.
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Although morbidity associated with hematologic
malignant diseases in elderly patients is higher than
that in younger patients [1], elderly patients are less
likely to be candidates for allogeneic stem cell trans-
plantation, because of the fact that they are more likely
to have comorbid organ conditions, either clinically or
subclinically, which result in a higher rate of proce-
dure-related mortality [2], and that they are less likely
to have HLA-matched related donors available, as
siblings also tend to be elderly.
The development of reduced-intensity condition-
ing (RIC) for transplants, which results in less toxicity
and depends largely on graft-versus-tumor effects
rather than high-dose therapy to eliminate malignant
cells, has been shown to allow elderly patients to un-
dergo allogeneic transplants [3-5].The use of umbilicalcord blood transplantation (UCBT) has been increas-
ing because of the potential advantage of rapid avail-
ability and the lower risk of graft-versus-host disease
(GVHD), thus permitting less stringent HLA match-
ing [6,7]. The outcome of UCBT has been reported
to be similar to unrelated bone marrow in the myeloa-
blative setting [8-10]. UCBT with reduced-intensity
pretransplant conditioning (RI-UCBT) for adults,
mostly younger than 55 years old, has been increasingly
reported, and has been shown to be applicable even in
patients with a relatively low number of nucleated cells
for their body weight [11-16]. However, little informa-
tion has been available on whether elderly patients can
tolerate slower engraftment,more infectious complica-
tions [17], and the unique preengraftment immune re-
action (PIR) associated with UCBT [18,19]. PIR has
been described by us and others [18,19], characterized583
584 N. Uchida et al.by the symptoms induced possibly by hypercytokine-
mia, which sometimes cause severe organ damage and
fatal outcome. We therefore retrospectively evaluated
the use of the RI-UCBT in patients aged 55 and older
by analyzing engraftment, nonrelapse mortality
(NRM), GVHD, progression-free (PFS), and overall
survival (OS) to address the feasibility and effectiveness
of this method in older patients.
PATIENTS, MATERIALS, AND METHODS
Patients
This study included patients aged 55 and older who
underwent RI-UCBT at our institute from July 18,
2002 through October 28, 2005. Patients were eligible
for this study if they had any hematologic malignancies
at high risk for relapse or severe aplastic anemia (AA)
refractory to standard immunosuppressive therapy, as
well as if they were unable to find suitable related or
unrelated bone marrow (BM)/peripheral blood (PB)
donors within reasonable time periods relative to their
disease conditions. Patients with acute leukemia could
be at first remission but at high risk for relapse because
of adverse cytogenetic abnormalities, have a prior
hematologic disorder, or be at any status beyond first
remission. Patients with myelodysplastic syndrome
(MDS) had to be refractory anemiawith excess of blasts
or chronic myelomonocytic leukemia, or have refrac-
tory anemiawith transfusion dependency and/or severe
neutropenia. Patients with chronic myeloid leukemia
(CML) had to be beyond the first chronic phase. Lym-
phoma patients had to be beyond the first remission
except those with acute or lymphoma type adult T
cell leukemia. Patients who had end-stage organ dys-
function (DLco \30% predicted or LVEF \35%),
or active serious infection at the time of transplantation
were not eligible. All patients gave written informed
consent, and the studywas approved by the appropriate
institutional review boards.
Donor Selection
UCB units were obtained from Japanese Cord
Blood Bank Network. HLA-A and HLA-B antigens
were identified by serologic typing. HLA-DRB1 alleles
were determined by high-resolution molecular typing
using polymerase chain reaction (PCR) sequence-spe-
cific primers. UCB grafts had at least 4 of 6 HLA-A, B
antigens, and DRB1 alleles that were matched to the
recipient and had a cryopreserved cell dose of at least
1.8 107nucleatedcells per kgof recipient bodyweight.
The median total nucleated cell number and median
CD341 cell number were 2.8 (range: 1.8–5.2) 107/kg
and 0.84 (0.11-3.28)  105/kg, respectively.
Patient Characteristics
Seventy consecutive patients were included in this
study. Their characteristics are shown in Table 1.Of these 70 patients, 25 were women and 45 were
men. Their median age was 61 years (range: 55-79
years). The patients’ diagnoses included acute myeloid
leukemia (AML; n 5 28), acute lymphoblastic leuke-
mia (ALL; n 5 11), MDS (n 5 3), CML (n 5 4),
non-Hodgkin lymphoma (NHL; n 5 8), adult T cell
Table 1. Patient and Donor Umbilical Cord Blood Characteristics
Characteristic No. (%) of Patients
Sex
Male 45 (64)
Female 25 (36)
Age (years)
Median (range) 61 (55-79)
Age distribution (years)
55 to 59 31 (44)
60 to 64 16 (23)
65 to 69 17 (24)
At least 70 6 (9)
Diagnosis
AML 28 (40)
MDS 3 (4)
CML 4 (6)
ALL 11 (16)
NHL 8 (11)
ATL 12 (17)
MM 1 (1)
PCL 1 (1)
AA 2 (3)
HCT-CI
0 24 (34)
1 25 (36)
2 11 (16)
3 or greater 10 (14)
History of prior chemotherapy
Yes 59 (84)
No 11 (16)
History of prior documented infections
Yes 15 (21)
No 55 (79)
Disease status
Standard risk 15 (21)
High risk 55 (79)
Conditioning regimen
Flu/Mel/TBI 65 (93)
Flu/Bu/TBI 4 (6)
Others 1 (1)
GVHD prophylaxis
Cyclosporine A alone 37 (53)
Tacrolimus alone 33 (47)
HLA disparity to UCB
5/6 9 (13)
4/6 61 (87)
Sex mismatch to UCB
Yes 51 (73)
No 19 (27)
AML indicates acute myeloid leukemia; MDS, myelodysplastic syn-
drome; CML, chronic myeloid leukemia; ALL, acute lympho-
blastic leukemia; NHL, non-Hodgkin lymphoma; ATL, adult
T cell leukemia; MM, multiple myeloma; PCL, plasma cell leu-
kemia; AA, aplastic anemia; Flu, fludarabine; Mel, melphalan;
TBI, total body irradiation; Bu, busulfan; UCB, umbilical cord
blood: HCT-CI, hematopoietic cell transplantation-specific
comorbidity index.
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tiple myeloma (n5 1), and AA (n5 2). Three patients
had previous autologous hematopoietic cell transplan-
tation. For disease status, those with hematologic ma-
lignancies in first or second complete remission at the
time of transplant, those in the chronic phase or accel-
erated phase of CML, those with refractory anemia of
MDS, and those with nonmalignant diseases were de-
fined as being at standard risk (n 5 15), whereas those
inother situationsweredefinedasbeing at high risk (n5
55). Patients were assessed for their comorbidity by the
previously reported scoring system [20].
Conditioning Regimens and Postgrafting
Immunosuppression
Pretransplant conditioning varied, and was deter-
mined by each attending physician according to the
patient’s disease, disease status, and history of prior
therapy. Sixty-five patients underwent conditioning
regimens with 125-180 mg/m2 of fludarabine (Flu;
25 mg/m2 for 5 days or 30 mg/m2 for 6 days), along
with 80 mg/m2 of melphalan (Mel; 40 mg/m2 for 2
days) and total-body irradiation (TBI) at a total dose
of 4 Gy for 63 and 2 Gy for 2. Four patients in rela-
tively poor performance status were conditioned with
busulfan to avoid severe gastrointestinal tract toxicity
induced by the use of Mel. One patient underwent
a conditioning regimen with thiotepa (5 mg/kg for 2
days) in addition to 125 mg/m2 of Flu and 80 mg/m2
of Mel, because of the urgent transplant schedule
that did not allow access to TBI. Valproate sodium
(300 mg/day) was administered to all patients who re-
ceived Bu. Immunosuppressive therapy with cyclo-
sporine A (CsA, 3 mg/kg continuous infusion, aiming
for a serum concentration of 250-400 ng/mL) or tacro-
limus (Tac, 0.03 mg/kg continuous infusion, aiming
for 12-17 ng/mL) was started on day 21. CsA was
used for patients in the early phase of this study, and,
based on our early experience of high early mortality
related to PIR in the patients with CsA prophylaxis,
Tac was subsequently used to substitute for CsA.
Supportive Care
Prophylactic antibiotics, including fluorquinolone,
fluconazole, andacyclovir,wereused routinely. Patients
received ganciclovir or foscarnet for any sign of a cyto-
megalovirus reactivation, such as isolation of CMV or
detection of viral proteins (pp65) or nucleic acid in
any body fluid or tissue specimen. Pneumocystis jiroveci
prophylaxis included trimethoprim-sulfamethoxazole
as first-line therapy.
Definition of Engraftment, Preengraftment
Immune Reaction, and End Points
OS ands PFS were computed from the date of
transplantation. Engraftment was defined as absolute
neutrophil count .0.5  109/L for 3 consecutivedays. Chimerism was assessed using fluorescent in
situ hybridization in sex-mismatched donor-recipient
pairs. In sex-mismatched pairs, PCR for variable num-
ber of tandem repeats was used with donor cells de-
tected at a sensitivity of 10%. Whole blood or BM
cells were assessed at the time of granulocyte engraft-
ment. PIR was characterized by the presence of at least
2 of the following symptoms with no direct conse-
quences of infection or adverse effects of medication
6 or more days before engraftment, as described previ-
ously [12,18]; a high fever (.38.5C), skin eruptions,
diarrhea, jaundice (serum levels of total bilirubin
.2.0 mg/dL), or body weight gain .10% of baseline.
NRM was defined as death in the absence of disease
progression. Deaths occurring after disease progres-
sion were categorized as relapse regardless of the cause
of death. Infection was considered the cause of death
when bacterial, viral, or fungal infection was deter-
mined to be the proximate cause of death in patients
who had not relapsed. Patients underwent BM aspira-
tion at the time of engraftment or if clinically indicated.
Relapse for AML, ALL, CML, or MDS was deter-
mined by flow cytometric, morphologic, or cytoge-
netic evidence of malignant or dysplastic cells with
clonal markers similar to those observed before trans-
plantation. Relapse for NHL was defined as progres-
sive adenopathy or BM involvement. Acute and
chronic GVHD (aGVHD, cGVHD) were defined
and graded by standard criteria [21]. The following fac-
tors were considered potential predictors of outcomes:
recipient’s age, disease risk (standard versus high),
ECOG performance status, HCT-specific comorbid-
ity index score, history of prior chemotherapy (all cy-
toreductive chemotherapy excluding hydroxyurea and
imatinib mesylate), history of prior documented infec-
tions (infectious episode with positive culture results
for bacterial or yeast infections, and at least probable
diagnosis of mold infection by EORTC/NIH-MSG
criteria [22]), number of total nucleated cord blood
cells, number of CD341 cells, HLA disparity, condi-
tioning regimen, GVHD prophylaxis, grade of
aGVHD, and the presence or absence of PIR.
Statistical Methods
OS was calculated from the day of transplantation
until death from any cause or last follow-up. Disease-
free survival (DFS) was calculated from the day of
transplantation until relapse or death from any cause
or last follow-up. The probabilities of survival and
DFS were estimated and plotted using the Kaplan-
Meier method [23]. Relapse and NRM rates were esti-
mated using cumulative incidence analysis and were
considered competing risks [24]. Similarly, in the anal-
ysis of GVHD rates, death because of other causes or
relapse leading to early withdrawal of immune sup-
pression were considered competing risks. The effect
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survival probabilities was studied with the log-rank
test. A Cox proportional hazard model with limited
variables because of small sample was used to deter-
mine the significance of multiple variables in deter-
mining these outcomes. Cumulative incidence curves
were drawn using Gray’s method [25].
RESULTS
Engraftment
Ten of the 70 patients were not evaluable for donor
engraftment because of early death (before 28 days
posttransplant) from disease progression (n 5 1), in-
fection (n 5 7), and complications of central nervous
system (n5 2). Of the 60 evaluable patients, the cumu-
lative incidence of primary donor engraftment was
92% at a median of 18 days after transplantation
(range: 11-53 days). Platelet recovery .20  109/L
was observed in 38 patients (63%), at a median of 35
days (range: 25-95 days). All patients required transfu-
sions of platelets and red blood cells. Recovery of neu-
trophil counts.0.5 109/L did not occur in 5 patients
who survived beyond 28 days posttransplant; these pa-
tients were classified as primary graft failures. Two of
these patients received secondary RI-UCBT and died
of infection. The remaining 3 patients died of infec-
tion. All engrafting patients without BM relapse were
complete donor chimeras beyond 1 month after trans-
plantation (data not shown). Remarkably, all 3 evalu-
ated patients of 10 who died before day 28 showed
complete donor chimerism (94%, 100%, and 94.6%
on days 12, 15, and 20 posttransplant, respectively).
PIR and GVHD
Forty-three patients experienced clinical symp-
toms defined as PIR, as described previously [12,18].
Patients who received Tac as GVHD prophylaxis
tended to have a lower chance of experiencing PIR
compared with those who received CsA, although dif-
ferences were not statistically significant (53% versus
72%, respectively; P 5 .1).
Among 54 evaluable patients, 33 patients (61%)
developed aGVHD of grade II or higher, including
23 patients (43%) who developed that of grade III or
IV. Of the 30 patients who survived longer than 100
days posttransplant, 12 (40%) developed cGVHD,
including 7 with limited and 5 with extensive form
(Table 2).
Survival, Disease Progression, and NRM
At the time of analysis, 20 of 70 patients survived
a median of 512 days (range: 103-1213 days) after
transplantation. The Kaplan-Meier estimates of OS
and PFS at 2 years were both 23% (Figure 1). The me-
dian OS time was 114 days (range: 7–1213 days), and
themedian PFS time was 92 days (range: 7–1213 days).
Eighteen patients (26%) showed progression of
the underlying disease at a median of 134 days (range:
13–785 days) after transplantation, and 15 of these
patients died of their disease.
Thirty-seven patients died of nonrelapse causes
(Table 3). Nineteen of them were from infections,
which was the leading cause of NRM. Among 33
deaths observed before day 100 posttransplant, 30
were from nonrelapse causes and 3 from disease pro-
gression. The cumulative incidences curves of NRM
and disease progression are shown in Figure 2.
Factors Contributing to OS and NRM
In univariate analyses, survival was associated with
recipient’s age (P5 .01), disease risk (P\.01), aGVHD
(P\ .01), and PIR (P\ .01), with favorable outcomes
in younger recipients (\61 years), those with standard
risk, those with lower grade aGVHD (grade 0-II), and
thosewithout PIR (Figure 3A-D). Potential risk factors
such as ECOG performance status, HCT-specific co-
morbidity index score, history of prior documented in-
fection, history of prior chemotherapy, HLA disparity,
Table 2. The Incidence and Severity of Graft-versus-Host Disease
(GVHD)
Patients (n 5 54)
No. (%)
Acute GVHD 45 (83)
Grade II-IV 33 (61)
Grade III-IV 23 (43)
Patients (n 5 30)
No. (%)
Chronic GVHD 12 (40)
Limited 7 (23)
Extensive 5 (17)
Figure 1. OS and PFS estimates for 70 patients with hematologic
diseases treated with RI-UCBT.
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fused CD341 cells, and cGVHD did not reach statisti-
cal significance.
In the Cox regression analyses, recipient’s age
equal to or older than 61 (hazard ratio [HR] 5 3.33;
95% confidence interval [CI] 5 1.39-7.14; P 5 .006),
high risk disease (HR 5 3.33; 95% CI 5 1.01; 8.33
P 5 .049), grade III-IV aGVHD (HR 5 2.5; 95%
CI 5 1.28; 5.88 P 5 .0002), and the presence of PIR
(HR5 2.5; 95% CI5 1.14; 6.25 P5 .023) were asso-
ciated with statistically worse OS (Table 4). No other
factors were significantly or suggestively associated
with OS.
Regarding toxicity, multivariate analyses revealed
that GVHD prophylaxis (HR 5 3.9, 95% CI 5 1.3-
11.6 for CsA versus Tac; P5 .01) and aGVHD (HR5
5.7, 95% CI 5 2.1-15.7 for grade III–IV versus 0-II;
P 5 .001) were associated with NRM.
DISCUSSION
This study was undertaken to evaluate engraftment
and toxicities in elderly patients with advanced hema-
tologic diseases who received UCBT matched for at
Table 3. Causes of Death
Patients (n 5 70)
No. (%)
NRM 37 (53)
Infection 19 (27)
GVHD 9 (12)
IP 4 (6)
TMA 3 (4)
Others 2 (3)
Relapse 13 (19)
Total 50 (71)
NRM indicates nonrelapse mortality; GVHD, graft-versus-host
disease; IP, interstitial pneumonia; TMA, thrombotic microangi-
opathy.
Figure 2.NRM and disease progression. Cumulative incidence esti-
mates of NRM and disease progression for all 70 patients.least 4 loci ofHLA-A, -B, and –DRB1 using a nonmye-
loablative regimen.
Several observations were made. First and fore-
most, RI-UCBT was a feasible treatment strategy for
elderly patients with a successful engraftment rate of
92% without secondary graft failure except disease
progression. The average interval between transplant
and neurtophil recovery to 500/mL was 18 days, which
is comparable to previously reported in RIC [11,12].
The chimerism study confirmed rapid engraftment
of donor cells in all engrafted patients. Together
with the fact that all 3 evaluated patients who died
before day 28 already achieved complete donor chime-
rism, these data indicate that our pretransplant condi-
tioning regimens, mainly consisting of Flu, Mel, and
TBI, along with single calcineurin inhibitors for
GVHD prophylaxis, can exert sufficient immunosup-
pressive effects that allow engraftment of CB cells.
Compared to the conditioning regimen containing
cyclophosphamide reported from Minnesota group
[11], which allow mixed chimeric state especially for
myeloid lineages during the early period of posttrans-
plant, our conditioning is more powerful in eradi-
cating host myeloid cells as well, which may have
beneficial effect for rapid control of myeloid malig-
nancies. The OS and PFS were estimated as both
23% at 2 years posttransplant, almost comparable
to or slightly less than the data reported previously
[15,16,26], which can be reasonably explained by
higher age range and poor disease status before trans-
plant in this study cohort, which can be further sup-
ported by the result of subgroup analysis indicating
those with standard disease status showed much better
outcome (Figure 3B).
UCBT has been associated with lower incidence of
aGVHD, possibly because of the immunologic naı¨vety
of transplanted lymphocytes; however, this naı¨vety rai-
ses a concern about whether transplanted cells will
have sufficient antimalignant activity. Several reports
indicate the in vivo antimalignancy effect of cord blood
cells [27-30]. Cumulative incidence of disease progres-
sion at 2 years posttransplant in our series was 24%,
which is comparable to those previously reported
[15,16,26]. It plateaued later than 795 days, indicating
that our RI-UCBT treatment protocol offered fairly
good disease control.
The incidence of GVHDwas higher than previous
reports in RIC [11,12], and was almost comparable to
those of BM transplants, PB cell transplants, or UCBT
with conventional conditioning [8-10,31-36]. Because
of the poor disease status of the majority of patients in-
cluded in this study, GVHD prophylaxis was initially
planned to be less intensive with single calcineurin in-
hibitors. Older patients’ age [37] or high incidence of
infectious complications, which possibly induced ex-
cessive inflammatory cytokine secretions, could have
been relevant to this result [38].
588 N. Uchida et al.Figure 3.OS estimates after RI-UCBT (n5 70). (A) Effect of age. (B) Effect of disease status. (C) Effect of severity of aGVHD. (D) Effect of PIR.Although RI-UCBT has been a feasible approach
in terms of engraftment, a significant number of pa-
tients died from treatment-related complications.
NRM was close to 3 times higher than mortality
from relapse or disease progression, and most NRM
occurred within 100 days posttransplant. Of 37 deaths
because of NRM, 19 were from infection. Delayed en-
graftment relative to other stem cell sources such as
BM or PB cells has been suggested to account for the
higher rate of infectious complications after UCBT
[32,39,40], but the time to engraftment in our series
of patients was not delayed. Higher grade of aGVHD
and the presence of PIR were found to be significantly
associated with poor OS in multivariate analysis, indi-
cating that immune-mediated events have strong
impact on patients’ outcome (Table 4). PIR is the syn-
drome observed in our setting of RI-UCBT. Although
the mechanism behind PIR has not been investigated
extensively yet, it is assumed to be reflecting allo-
immune event, given our experience that more inten-
sive GVHD prophylaxis with Tac had tendency to
decrease the incidence of PIR.Moreover, development
of PIR may have been suppressed in reported cases
from other institutes that utilized additional agents to
calcineurin inhibitors, such as methotrexate [10,19],
antithymocyte globulin [31], or mycophenolate mofe-
til [16]. There has been a similar early immune reac-
tion-like syndrome reported as ‘‘hyperacute GVHD’’
observed following BM or PBSC transplant, and re-
sponded poorly to corticosteroids compared to tradi-
tional aGVHD [41,42]. The incidence of PIR was
higher than that of hyperacute GVHD, and further in-
vestigation on biologic mechanisms may help us definePIRmore precisely relative to other immune-mediated
diagnosis and develop optimal treatment approach.
The presence of PIR was shown to cause more NRM
than the absence in univariate analysis (P 5 .02),
although it did not reach statistical significance inmulti-
variate analysis. Thus, better management of immune-
mediated complications will be the key to reduceNRM
and improveOS. Based on our early experience of high
early mortality related to PIR in the patients with CsA
prophylaxis, Tac was subsequently used to substitute
for CsA, because Tac was shown to be more potent
than CsA in BM transplant [43-45]. Patients who re-
ceived Tac as GVHD prophylaxis had less chance of
experiencing PIR compared with those who received
CsA and had less NRM, indicating the potential bene-
fit of using Tac as a standard agent for GVHDprophy-
laxis. Adding methotrexate, mycophenolate mofetile,
or sirolimus to the calcineurin inhibitor may further
improve the final outcome [10,11,46,47]. Older age
was another factor that influenced OS with statistical
significance, even within the age range studied
(Figure 3A and Table 4). Patients aged 61 years and
older experienced more NRM than patients younger
than 61 years (65% versus 39%), whereas their death
rate because of disease progression was comparable
(19% versus 18%), suggesting the vulnerability of
higher aged population to procedure toxicity. Al-
though the possible impact of slight variation in condi-
tioning regimen to the outcome cannot be excluded, it
is unlikely, because the great majority (93%) were con-
ditioned with Flu/Mel/TBI regimen fairly uniformly,
and comparison between Flu/Mel/TBI and others
did not reach statistical significance.
RI-UCBT in the Elderly 589In conclusion, this is the first study specifically fo-
cusing on elderly patients aged 55 years and older with
advanced hematologic diseases to show the feasibility
of RI-UCBT. Older age per se cannot be considered
to be contraindication to RI-UCBT, although a high
NRM has been observed. Further optimization of
the treatment protocol, such as immunosuppressive
therapy for GVHD prophylaxis, is warranted to estab-
lish the safety of this promising treatment strategy for
elderly patients with advanced hematologic diseases.
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